A combination treatment of IFN-α2b and IFN-γ accelerates viral clearance and control inflammatory response in COVID-19: Preliminary results of a randomized controlled trial

• Egile Nagusiak: Esquivel-Moynelo Idelsis (Egilea), Pérez-Escribano Jésus (Egilea), Duncan-Roberts Yaquelin (Egilea), Vázquez-Blomquist Dania (Egilea), Bequet-Romero Mónica (Egilea), Báez-Rodríguez Lisandra (Egilea), Castro-Ríos Jésus (Egilea), Cobas-Cervantes Lisbeth (Egilea), Pagé-Calvet Ernesto (Egilea), Travieso-Pérez Saily (Egilea), Martinez-Suarez Claudia (Egilea), Campa-Legra Ivan (Egilea), Fernandez-Masso Julio (Egilea), Camacho-Rodriguez Hamlet (Egilea), Díaz-Gálvez Marisol (Egilea), Sin-Mayor Adriana (Egilea), García-Sánchez Maura (Egilea), Martínez-Martín Sara (Egilea), Alonso-Valdés Marel (Egilea), Hernández-Bernal Francisco (Egilea), Nodarse-Cuni Hugo (Egilea), Bello-Garcia Dianela (Egilea), Canaan-Haden Ayala Camila (Egilea), Gonzáles-Moya Isabel (Egilea), Beato-Canfuk Abrahan (Egilea), Vizcaino-Cesar Tania (Egilea), Guillén-Nieto Gerardo (Egilea), Muzio-González Verena (Egilea), Fish Eleanor (Egilea), Bello-Rivero Iraldo (Egilea)
• Formatua: Liburua
• Argitaratua: Annals of Antivirals and Antiretrovirals - Peertechz Publications, 2021-06-15.
• Gaiak: Research Article
• Sarrera elektronikoa: Connect to this object online.

<p>Background: There is in vitro evidence that a combination of IFN-α and IFN-γ acts synergistically to inhibit SARS-CoV replication. We conducted a randomized controlled clinical trial to evaluate the safety and therapeutic efficacy of administration of a combination of IFN-α and IFN-γ for CO...